Olema Pharmaceuticals (NASDAQ: OLMA) investors approve board slate, pay plan and Ernst & Young
Rhea-AI Filing Summary
Olema Pharmaceuticals, Inc. reported the results of its annual stockholder meeting held on June 17, 2026. Stockholders elected four Class III directors—Sean Bohen, Scott Garland, Yi Larson, and Andrew Rappaport—to serve until the 2029 annual meeting and until their successors are elected and qualified.
Stockholders also approved, on an advisory basis, the executive compensation program, with about 68 million votes in favor and relatively few votes against or abstaining. In addition, they strongly ratified the Audit Committee’s selection of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. No other matters were brought to a vote.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Meeting date: June 17, 2026
Votes for Bohen: 67,474,365 votes
Votes for Garland: 66,184,382 votes
+4 more
7 metrics
Meeting date
June 17, 2026
Date of annual meeting of stockholders
Votes for Bohen
67,474,365 votes
Election of Sean Bohen as Class III director
Votes for Garland
66,184,382 votes
Election of Scott Garland as Class III director
Votes for Larson
50,371,668 votes
Election of Yi Larson as Class III director
Votes for Rappaport
67,276,575 votes
Election of Andrew Rappaport as Class III director
Say-on-pay support
67,969,902 votes
Advisory vote for executive compensation
Auditor ratification for
75,811,449 votes
Ratification of Ernst & Young LLP for 2026
Key Terms
broker non-votes, advisory basis, independent registered public accounting firm, Audit Committee, +1 more
5 terms
broker non-votes financial
"and the number of abstentions and broker non-votes with respect to each matter."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
advisory basis financial
"The Company’s stockholders approved, on an advisory basis, the compensation awarded"
independent registered public accounting firm financial
"as the Company’s independent registered public accounting firm for the year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Audit Committee financial
"the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
definitive proxy statement regulatory
"in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
FAQ
What key decisions were made at Olema Pharmaceuticals (OLMA) 2026 annual meeting?
Stockholders elected four Class III directors through 2029, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, with no other matters submitted for action.
Which directors were elected at Olema Pharmaceuticals (OLMA) 2026 annual stockholder meeting?
Sean Bohen, Scott Garland, Yi Larson, and Andrew Rappaport were elected as Class III directors. They will serve until Olema’s 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified under the company’s governance structure.
How did Olema Pharmaceuticals (OLMA) stockholders vote on executive compensation in 2026?
Stockholders approved the company’s named executive officer compensation on an advisory basis, with 67,969,902 votes for, 653,979 against, and 15,867 abstentions, plus 7,496,139 broker non-votes. This supports the compensation program disclosed in the April 29, 2026 proxy statement.
Who is Olema Pharmaceuticals’ (OLMA) independent registered public accounting firm for 2026?
Stockholders ratified the Audit Committee’s selection of Ernst & Young LLP as Olema’s independent registered public accounting firm for the year ending December 31, 2026, with 75,811,449 votes for, 271,918 against, and 52,520 abstentions recorded in the voting results.
Were there any other matters voted on at Olema Pharmaceuticals (OLMA) 2026 annual meeting?
No. Beyond director elections, the advisory vote on executive compensation, and ratification of Ernst & Young LLP as auditor, no other matters were submitted for stockholder action at Olema Pharmaceuticals’ 2026 annual meeting, according to the disclosed voting results.
How strong was support for Olema Pharmaceuticals (OLMA) 2026 director nominees?
Support was high for most nominees. For example, Sean Bohen received 67,474,365 votes for and 1,165,382 withheld, with 7,496,139 broker non-votes. Similar strong majorities were recorded for Scott Garland and Andrew Rappaport, while Yi Larson received more withheld votes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
